“With Anna, we get a CEO who has relevant cell biology knowledge and deep and long experience in complex sales. Of central importance is understanding customer needs and translating them into deliveries with a high degree of customer benefit. Anna is a leader with a good ability to motivate and develop teams to achieve set goals,” says Chairman Arne Nabseth.

Anna Hellergård

Within medtech, Anna has seven years of experience as Product Manager at Mettler Toledo with responsibility for new product launches. She also has extensive experience in digitalization and strategic communication. Anna most recently comes from HEAILTH as Director of Strategy & Business Development, before that she was COO of Blendow Lexnova.

Current CEO and founder Teodor Aastrup will, as Head of Research, focus on ensuring that Attana’s deliveries are of the highest quality and help current and future customers get the best possible value and benefit from Attana’s unique technology. Teodor will also take responsibility for product and patent strategy, further development of instruments and technology, and for production.

“I am honored and excited to be entrusted to lead Attana in the next phase of the company’s development. Attana’s technology has significant, yet untapped potential to fundamentally change drug development. Our platform provides pharmaceutical companies, CROs and research institutions with a powerful tool to identify promising candidates early, avoid costly mistakes and accelerate the path to market. I look forward to collaborating with our talented team, our partners and shareholders to realize Attana’s full potential and establish the company as a leading player in real-time measurement of biological interactions,” says Anna Hellergård.